Trial · NCT02408484
Results by group53
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 53
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 4-point Haemostatic Efficacy Scale | Investigator Assessment | Excellent | 5 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 4-point Haemostatic Efficacy Scale | IDMEAC Assessment | Excellent | 6 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 4-point Haemostatic Efficacy Scale | Investigator Assessment | Good | 1 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 4-point Haemostatic Efficacy Scale | IDMEAC Assessment | Good | 2 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 4-point Haemostatic Efficacy Scale | Investigator Assessment | Moderate | 1 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 4-point Haemostatic Efficacy Scale | IDMEAC Assessment | Moderate | 0 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 4-point Haemostatic Efficacy Scale | Investigator Assessment | None | 1 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 4-point Haemostatic Efficacy Scale | IDMEAC Assessment | None | 0 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 2-point Haemostatic Efficacy Scale | Investigator Assessment | Success | 6 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 2-point Haemostatic Efficacy Scale | IDMEAC Assessment | Success | 8 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 2-point Haemostatic Efficacy Scale | Investigator Assessment | Failure | 2 | Participants | |
| Overall Clinical Assessment of the Haemostatic Efficacy of Octafibrin in the On-demand Treatment of the First Documented Bleeding Episode of Each Patient Based on a 2-point Haemostatic Efficacy Scale | IDMEAC Assessment | Failure | 0 | Participants | |
| Single-dose Pharmacokinetics of Octafibrin: Area Under the Concentration-time Curve Normalised (AUCnorm) | Octafibrin | 1.419 | Standard Deviation 0.4385 | h*kg*g/L/mg | |
| Single-dose Pharmacokinetics of Octafibrin: Response - Incremental in Vivo Recovery (IVR) | Octafibrin | 1.592 | Standard Deviation 0.3224 | mg/dL/(mg/kg) | |
| Single-dose Pharmacokinetics of Octafibrin: Terminal Elimination Half-life (t1/2) | Octafibrin | 84.356 | Standard Deviation 34.2658 | hours | |
| Single-dose Pharmacokinetics of Octafibrin: Maximum Plasma Concentration (Cmax) | Octafibrin | 1.559 | Standard Deviation 0.3183 | g/L | |
| Single-dose Pharmacokinetics of Octafibrin: Time to Reach Maximum Plasma Concentration (Tmax) | Octafibrin | 1.154 | Standard Deviation 0.5547 | hours | |
| Single-dose Pharmacokinetics of Octafibrin: Mean Residence Time (MRT) | Octafibrin | 114.332 | Standard Deviation 37.9732 | hours | |
| Single-dose Pharmacokinetics of Octafibrin: Volume of Distribution (Vss) | Octafibrin | 81.651 | Standard Deviation 15.2735 | mL/kg | |
| Single-dose Pharmacokinetics of Octafibrin: Clearance (Cl) | Octafibrin | 0.756 | Standard Deviation 0.1872 | mL/h/kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02408484/results